BIOX: Stable 4Q26 revenues and improved cost controls offset ongoing net losses and portfolio transitions

Revenues remained stable in 4Q26, with strong Crop Nutrition growth offsetting declines elsewhere, while FY26 revenues fell 18% year-over-year. Cost actions improved SG&A and Adjusted EBITDA, but net losses persisted. Focus remains on liability management, gross profit expansion, and operational ef…